Adjunctive Mindfulness During Opioid Tapering for patientS With Chronic Pain (The AMOS Study)
CompletedNot applicableNCT06268522
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study is a Randomized Controlled Trial exploring the effects of a Mindfulness interventions in reducing pain interference and opioid dose in patients with Chronic Low Back Pain. A total of 200 opioid-using patients with chronic pain, male and female participants will be enrolled, with a need for 160 completers. Patient will be randomly assigned into the Mindfulness-Oriented Recovery Enhancement or the Psychoeducation comparison control group.
Study details
- Official title
- Adjunctive Mindfulness During Opioid Tapering for Patients With Chronic Pain
- Conditions
- Interventions
- Behavioral: Mindfulness-Oriented Recovery Enhancement: (MORE) group
- Behavioral: Psychoeducation
- Sponsor
- Brigham and Women's Hospital
- Start date
- 2024-02-01
- Primary completion
- 2025-06-28
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion criteria: * age\>18yo * Chronic Low Back Pain as seen on medical history as well as score of \>3 on pain visual analog scale (VAS) at the start of experimental sessions. * receiving prescription opioids for three or more months and planning to start tapering their opioids with their provider. * willing to be randomized to one of the two behavioral treatment. Patients referred or self-referred to the study from an outside clinic will also be able to participate (we will be in contact with their prescribing provider) * able and willing to perform/tolerate pain procedures (e.g., QST) * able to communicate fluently in English * able to use a smartphone or laptop for the virtual therapy program Exclusion criteria: * Current illicit substance use (e.g marijuana use will be exempted) at screening or during trial as verified by urine toxicology screen and/or self-report for all participants; * Medical condition known to influence QST or participation in the MORE intervention; serious psychiatric condition; * regular meditation practice * cognitive impairment * pregnancy * lack of English fluency * severe OUD * inability to provide informed consent.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06268522